Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Cytek Biosciences, Inc. (CTKB:NASDAQ), powered by AI.
Cytek Biosciences, Inc. is currently trading at $4.09. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Cytek Biosciences, Inc. on Alpha Lenz.
Cytek Biosciences, Inc.'s P/E ratio is -7.9.
“Cytek Biosciences, Inc. trades at a P/E of -7.9 (undervalued) with modest ROE of -18.0%.”
Ask for details →Cytek Biosciences Inc. is a biotechnology company that specializes in advancing the capabilities of flow cytometry technologies. Its primary function is to develop and deliver transformative, cost-effective products for researchers and clinicians in the life sciences sector. The company is renowned for its full spectrum flow cytometry systems, which allow users to conduct high-parameter cell analysis with higher accuracy and efficiency compared to traditional methods. This technology has significant implications in numerous fields, including immunology, oncology, and stem cell research, thereby supporting efforts in drug discovery, clinical trials, and personalized medicine. Cytek Biosciences Inc.'s offerings play a crucial role in enabling scientific discoveries and advancing public health initiatives. As a prominent player in the biotechnology market, Cytek contributes to pushing the boundaries of what's possible in cellular analysis, fostering breakthroughs that can lead to new therapeutic strategies and medical treatments.
“Cytek Biosciences, Inc. trades at a P/E of -7.9 (undervalued) with modest ROE of -18.0%.”
Ask for details →Cytek Biosciences, Inc. (ticker: CTKB) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 688 employees. Market cap is $522M.
The current price is $4.09 with a P/E ratio of -7.85x and P/B of 1.53x.
ROE is -18.05% and operating margin is -20.04%. Annual revenue is $201M.